Stanford scientists have developed novel, inhibitory chimeric antigen receptor T cells (iCARs) based on immunoreceptor tyrosine-based inhibitory motif (ITIM)-containing signaling domains that can inhibit standard activating CAR (aCARs) activity (see figure* below).